AlphAIalphai — Financial news for AI agents
BenzingaFEB 103 min read$PHIO

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients

Phio Pharmaceuticals (NASDAQ: PHIO) shares surged after the company announced positive Phase 1b clinical trial results for its lead candidate, PH-762. The trial for skin cancer patients showed an 85% pathological response rate and complete tumor clearance in a significant number of patients at the highest dose. The company plans an FDA submission in Q2 2026 to discuss future clinical study design.

Original reporting
Benzinga · Vandana Singh
Published Feb 10, 2026, 4:15 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Feb 10, 2026, 5:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients — source image
Source · Benzinga
Decision brief

The 30-second read

$PHIOBullishHigh
01

Why it matters

The successful trial outcomes are likely to boost investor confidence and stock valuation in the short term.

02

Market read

High relevance for biotech investors and traders focusing on oncology therapeutics.

03

What to watch

Potential regulatory hurdles, competition from other biotech firms, and market saturation could limit stock gains despite positive trial data.

Timing: Immediate, given the recent news and upcoming FDA submission in Q2 2026.

Background

Phio Pharmaceuticals is advancing its oncology pipeline with promising clinical trial results that could lead to FDA approval and commercial success.

Company-level read

Ticker impact

$PHIOBullishHigh confidence
Context

High relevance due to recent positive clinical trial results indicating potential for significant stock movement.

Expected impact

Expected short-term increase of 15-25% in stock price within the next 1-3 months, contingent on FDA approval process.

Evidence & confidence

The trial's high response rate and tumor clearance at the highest dose demonstrate clinical efficacy, which is likely to positively influence investor sentiment and stock valuation.

Market effects

Sector

Potential positive impact on biotech and oncology sectors, encouraging investor interest in cancer therapeutics.

Regional

Primarily US-focused, with possible influence on global biotech markets due to the company's NASDAQ listing.

Global

Moderate; while the trial results are promising, regulatory approval is required for broader market impact.

Counterpoint

What could challenge this read

The clinical trial results, while promising, are from early-phase studies; the risk of failure in subsequent phases remains high.

Key entities

  • Company
    Phio Pharmaceuticals

    Biotech firm focusing on cancer immunotherapy.

Read at source← All news

Related articles

AUG 6
$PHIOMedAI 8/10

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Phio Pharmaceuticals (NASDAQ: PHIO) reported Q2 2026 results for the quarter ended June 30, 2026 and updated its PH-762 siRNA program. Cash fell to $13.0M from $21.0M at Dec. 31, 2025. R&D rose to $3.1M and net loss widened to $4.1M. PH-762 Phase 1b (22 patients) completed in March; FDA documentation is being prepared and an FDA meeting is planned for Q3 2026. The company also launched a $6.36M ATM equity program.

finanznachrichten.de7 min
AUG 6
$PHIOMed

Phio Pharmaceuticals Corp. (PHIO): Results of Operations and Financial Condition

Phio Pharmaceuticals Corp. (PHIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_965504.htm EXHIBIT 99.1 ex_965504.htm Exhibit 99.1 Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale API, long term non-clinical to

SEC EDGAR 8-K6 min
AUG 10
$WIAMedAI 8/10

Wia Gold lines up $360m deal for Kokoseb project

WIA Gold said it signed indicative terms with Sprott Resource Lending to arrange $360m in construction debt for its Kokoseb gold project in Namibia, plus Sprott’s planned $15m purchase of WIA scrip in a future equity raise, subject to due diligence. WIA reported a definitive feasibility study forecasting 150,000 oz/y, 1.84m oz over 14 years, with $475m total capex and a 29% higher resource to 3.78m oz, using a $3,600/oz gold price.

miningmx.com6 min
AUG 10
$BAMedAI 9/10

Boeing Receives $75M Air Force Contract Action

Boeing said the U.S. Air Force awarded a $75 million undefinitized contract action to start initial production of the BSU-111/B payload delivery unit for the JDAM LR (GBU-75). Boeing said initial deliveries will go to the U.S. Navy. The BSU-111/B adds a wing-and-engine kit to extend range beyond 300 nautical miles, according to Boeing.

executivebiz.com4 min
AUG 10
$TSNMed

Taylor Farms recalls jalapeno products after salmonella outbreak

Taylor Farms is recalling about 20 fresh jalapeno-containing products, including dips, sandwiches, guacamole and sliced jalapenos, across 26 US states after a salmonella outbreak. The company said it has not identified illnesses linked to the products, but traced the source to a grower in Sinaloa, Mexico, and is switching suppliers. Retailers include Walmart, Target and Whole Foods.

bbc.com4 min
AUG 10
$LMTMed

Pentagon Presses for Weapons Surge as Iran War Drains U.S. Stockpiles

The Pentagon is pressing weapons makers to accelerate production after U.S. missile shortages tied to the Iran war. CSIS analysis says Patriot interceptor stocks fell from about 2,330 to 759-827, and THAAD from about 452 to 234-278. Reuters reports the Army used “virtually all” ATACMS and PrSM. The Pentagon is awarding contracts with Lockheed Martin and Northrop Grumman.

thenewamerican.com7 min